Why carry out this study?

Approximately equal numbers of men and women are affected by psoriatic arthritis (PsA), but female patients have been observed to have reduced treatment response and lower drug retention rates for tumor necrosis factor inhibitors.

It is important to understand if PsA treatments offer consistent benefits for both male and female patients.

This study assessed the efficacy of ixekizumab, an antileukin-17A inhibitor, in male and female patients with PsA.

What was learned from the study?

Male and female patients with PsA had significant differences in baseline disease characteristics as well as treatment response.

Understanding sex differences in PsA could improve outcomes in patients with prior inadequate response to treatment.